Protein and peptide medications are predominantly bioactive molecules, which means that their therapeutic actions are determined not only by their primary structure (amino acid sequence), but also by their secondary, tertiary, and, in some cases, quaternary structure. These structural properties govern the drug's biological activity and interactions with target cells or receptors.
Because of their intricacy, bioassays are crucial instruments for:
- Measuring drug concentration in biological fluids.
- assessing the biological activity of the medication.
Types of Bioassays
1. In Vivo Bioassays.
1. Conducting experiments on whole animals to directly assess biological activity.
2. Examples:
- Insulin: mouse blood glucose assay.
- IL-8 mobilizes neutrophils in rabbit bone marrow.
3. Advantages: Direct measurement of physiological activity.
4. Limitations:
- Time-consuming and labour-intensive.
- High variability but low sensitivity.
- Ethical considerations regarding animal use.
2. In vitro tissue or cell-based bioassays
1. Use cell cultures or tissue models to investigate medication action.
2. Examples:
- NGF (Nerve Growth Factor) stimulates the growth of chicken dorsal root ganglia.
- Oxytocin in a rat uterus model.
3. Advantages: More specific, sensitive, and repeatable than in vivo techniques.
Common Cell-Based Assays
1. Proliferation tests monitor cell proliferation; they are quick and sensitive but may lack specificity.
2. Antiproliferation assays are simple, sensitive, and specific methods for measuring growth suppression.
3. Cytopathic effect reduction assays (used for antiviral peptides such as interferons) are sensitive and intuitive.
Measurement Techniques:
- Direct cell count.
- Indirect approaches include MTT assays and isotope incorporation (^3H, ^14C).
- Polypeptide-cell interactions are investigated using immunodetection or enzyme breakdown techniques.
Limitations of bioassays
- Inactive metabolites cannot be quantified or tracked in vivo.
- The interference of endogenous molecules in serum may impair specificity.
- Threshold-dependent responses - some assays require a certain quantity of cytokines or substances to produce a response.
- Cell line variability - long-term cultures can acquire mutations that compromise assay reliability.
Summary
Bioassays for protein and peptide medicines are critical for determining biological activity and therapeutic efficacy. While in vivo assays are physiologically relevant, in vitro cell-based assays are more sensitive, specific, and reproducible, yet both methodologies have inherent limits that must be considered during drug development and pharmacokinetic research.
